You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Article metrics

Article menu
Download PDFPDF
Rheumatoid arthritis
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

 

Online download statistics by month:

Online download statistics by month: January 2022 to April 2025

AbstractFullPdf
Jan 20225639546421
Feb 20223318274259
Mar 20222067179150
Apr 20221133123105
May 20222309222168
Jun 20222419298237
Jul 20221740243160
Aug 20221345149113
Sep 20221697192130
Oct 20222370209155
Nov 20221529192144
Dec 202279712689
Jan 202381710788
Feb 20231400155107
Mar 20231025137110
Apr 2023109911082
May 2023115911869
Jun 20237277640
Jul 20237807853
Aug 20235585248
Sep 20236525937
Oct 20238087646
Nov 20237506144
Dec 20236154328
Jan 20244977434
Feb 20245747122
Mar 20246604432
Apr 20245116136
May 20245615537
Jun 20244884020
Jul 20245674246
Aug 20245204030
Sep 20244412821
Oct 20246013540
Nov 20245844449
Dec 20243223219
Jan 20252331911
Feb 202569107
Mar 202519163
Apr 202534311
Total4343444673291